No doubt the Covid situation in Germany and other hot spots has dampened the outlook for elective procedures. The Delta variant here seemed to come & go, and was probably overblown in the press. Also no doubt that MDT's outlook will be key to how the market reacts to Q2 earnings.

$Medtronic PLC(MDT)$  $Teleflex(TFX)$ $Moderna, Inc.(MRNA)$ $Pfizer(PFE)$